About iPSC Regenerative Medicine

Induced pluripotent stem cells (iPSCs) are established by introducing several factors to somatic cells such as skin cells. iPSCs can differentiate into the cells of a various tissues or organs (pluripotency) and grow indefinitely (proliferation). The objective of iPSC regenerative medicine is to restore cellular function by replacing dysfunctional tissues with cell therapy medicines, which are prepared via a differentiation process (a technique used to artificially change cells into those having specific functions),
and which have the same functions as healthy human tissues.

Replace damaged cells with regular cells

Pipeline in the Field of iPSC Regenerative Medicine

【Ophthalmology Area】

Under an exclusive license from RIKEN, we are developing a new treatment for age-related macular degeneration by transplanting iPSC-derived retinal pigment epithelial (RPE) cells. The joint development partner in Japan is Dainippon Sumitomo Pharma Co., Ltd.. Please refer to the page “About Age-Related Macular Degeneration (AMD)”.

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCR011 Wet AMD Japan
Joint development with Sumitomo Dainippon Pharma
Undergoing preparation for clinical trial
Development Code Indication Market Pre-clinical test Phase I Trial Phase II Trial Phase III Trial Apply-approve On the Market Progress Status

【Liver Disease】

Please refer to the page “About Liver Disease” involving a technology to create functional human organs using pluripotent stem cells (such as iPSC) in collaboration with Yokohama City University.

Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
HLCL041 Metabolic Liver Disease Japan
Joint research with Yokohama City University

Research Activities for the Next Generation

Healios is actively engaged not only in alliances with research institutes and companies around the world, but also in its own research activities, in order to quickly establish new technologies and know-how that can become the platform technologies of iPSC regenerative medicine products and accelerate their practical application.
Based on this strategy, we are advancing research activities on next-generation iPS cells, which use gene editing technology to reduce the risk of immune rejection regardless of HLA type. By combining these technologies, we are also making efforts toward the production of next-generation immuno-oncology cells.